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Abstract
Introduction:  In  recent  years,  total  androgen  blockade  therapy  for  advanced  prostate  cancer
has been  a  reasonable  option  to  castration  due  to  the  discovery  and  development  of  new  phar-
macologic agents.  In  this  study,  our  aim  was  to  evaluate  the  efﬁcacy  of  the  combined  treatment
of nilutamide  plus  buserelin  and  to  describe  the  occurrence  of  adverse  events  associated  with
this treatment.
Material  and  methods:  A  descriptive,  prospective  study  was  conducted.  Patients  with  advanced
prostate  cancer  receiving  nilutamide  plus  buserelin  were  evaluated  at  3,  6,  and  9  months.  The
primary endpoint  was  the  reduction  of  serum  levels  of  prostate-speciﬁc  antigen  (PSA).
Results:  One  hundred  and  four  patients  were  included  in  the  study,  but  only  67  patients  had
complete information  and  thus  were  evaluated  in  the  efﬁcacy  analysis:  65  (97.0%)  achieved
a 50%  reduction  in  PSA  level,  compared  with  the  baseline  value,  and  2  patients  achieved  a∗ Corresponding author at: San Faustino M842, L12, Pedregal Santa Úrsula, CP 04600 Ciudad de México, Mexico. Tel.: +52 5585810069.
E-mail address: ravelma@urocirugia.com (R.F. Velázquez-Macías).
ttp://dx.doi.org/10.1016/j.uromx.2016.10.001
007-4085/© 2016 Sociedad Mexicana de Urolog´ıa. Published by Masson Doyma Me´xico S.A. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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decrease  <10  ng/ml.  The  combination  therapy  was  well  tolerated,  given  that  only  7  patients
(6.7%) presented  with  mild  adverse  events  that  did  not  require  treatment  suspension  or  other
speciﬁc maneuvers.
Conclusions:  Treatment  with  nilutamide  plus  buserelin  appears  to  be  safe  and  effective  in
controlling  tumor  activity  in  advanced  prostate  cancer  patients.
© 2016  Sociedad  Mexicana  de  Urolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Evaluación  de  la  eﬁcacia  de  buserelina  más  nilutamida  en  pacientes  mexicanos  con
cáncer  prostático  avanzado
Resumen
Introducción:  En  an˜os  recientes  la  terapia  de  privación  máxima  de  andrógenos  para  el  cáncer
avanzado de  próstata  constituye  una  opción  razonable  a  la  castración  debido  al  descubrimiento
y desarrollo  de  nuevos  agentes  farmacológicos.  En  este  estudio  nuestro  objetivo  fue  describir
la eﬁcacia  del  tratamiento  combinado  de  nilutamida  más  buserelina  y  la  ocurrencia  de  efectos
adversos asociados  con  este  tratamiento.
Material  y  métodos:  Se  realizó  un  estudio  descriptivo,  prospectivo,  en  pacientes  con  cáncer
de próstata  avanzado,  los  cuales  recibieron  nilutamida  más  buserelina  y  fueron  evaluados  a  los
3, 6  y  9  meses.  El  desenlace  primario  fue  el  descenso  del  nivel  sérico  de  antígeno  prostático
especíﬁco.
Resultados:  Se  incluyeron  104  pacientes,  pero  solo  67  fueron  considerados  porque  tuvieron
información  completa:  65  (97%)  lograron  un  descenso  del  50%  del  antígeno  prostático  especíﬁco
en comparación  con  el  inicial;  2  pacientes  lograron  un  descenso  <  10  ng/mL.  El  tratamiento
fue bien  tolerado  ya  que  solo  7  reportaron  efectos  adversos  (n  =  104);  estos  fueron  leves  y  no
requirieron suspender  el  tratamiento  u  otras  maniobras  especíﬁcas.
Conclusiones:  El  tratamiento  con  nilutamida  más  buserelina  fue  seguro  y  efectivo  para  controlar
la actividad  tumoral  en  pacientes  con  cáncer  de  próstata  avanzado.
© 2016  Sociedad  Mexicana  de  Urolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Prostate  cancer  (CaP)  is  the  most  common  cancer  in  men.1 In
Mexico,  it  is  the  second  cause  of  cancer-related  mortality.2
Even  though  prostate-speciﬁc  antigen  (PSA)  screening  has
led  to  some  over-diagnosis  and  over-treatment  of  CaP  in
younger  men,  older  men  tend  to  have  more  aggressive
tumors  and  few  receive  curative  therapy,  thus  explain-
ing  the  high  mortality  rate.3 Furthermore,  26--34%  of
patients  will  be  diagnosed  at  an  advanced  stage  of  the
disease.4
Androgen-deprivation  therapy  (ADT)  is  the  standard
approach  for  the  ﬁrst-line  treatment  of  advanced  CaP.5 ADT
can  be  achieved  with  the  use  of  hormonal  therapy  or  through
surgical  castration.
Androgens  have  a  stimulating  effect  on  the  androgen
receptors  within  the  epithelial  cells  of  the  prostate.  Once
the  hormones  are  located  intracellularly,  they  are  converted
into  dihydrotestosterone  (DHT)  by  5-alpha  reductase.  DHT
is  the  most  active  form  of  testosterone  and  carries  most  of
the  hormonal  functions,  including  cell  replication.6 Thus,
ADT  induces  apoptosis  in  susceptible  CaP  cells  by  reducing
the  synthesis  of  androgens  and  their  interaction  with  the
androgenic  receptor.7
m
s
tADT  is  usually  achieved  through  the  use  of  luteinizing
ormone-releasing  hormone  analog  or  a  gonadotropin-
eleasing  hormone  agonist,  such  as  buserelin.8 These  drugs
ust  be  combined  with  antiandrogens,  such  as  bicalutamide
r  nilutamide  (which  block  the  binding  of  DHT  to  the  andro-
en  receptor  in  the  nucleus  of  CaP  cells),  to  completely
lock  the  effect  of  testosterone.9
Whenever  these  drugs  are  used  in  combination,  the
esulting  therapy  is  called  maximum  androgen  blockade
MAB).10
Nilutamide  is  a  nonsteroidal  androgen  receptor  antago-
ist  that  shows  afﬁnity  for  androgen  receptors,  but  not  for
ther  steroid  receptors.  It  has  a  low  adverse  event  proﬁle
onsistent  with  androgen  depletion  (hot  ﬂushes,  gynecomas-
ia,  impotence,  and  gastrointestinal  disturbances),  and  has
een  shown  to  exert  a  signiﬁcant  PSA  response  in  advanced
aP  patients.11
Buserelin  is  a  synthetic  luteinizing  hormone-releasing
ormone  analog.  Its  intermittent  administration  stimulates
he  release  of  luteinizing  hormone  and  follicle-stimulating
ormone,  thus  increasing  testosterone  concentrations  in
ales,  whereas  its  continuous  administration  suppresses
ecretion  of  both  LH  and  FSH,  resulting  in  a  drop  in
estosterone  concentrations.  Its  adverse  event  proﬁle
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s  also  low  and  has  been  widely  studied  in  advanced
atients.12
Due  to  our  interest  in  the  use  of  MAB  on  PSA  levels  in
dvanced  CaP  patients,  we  conducted  a  study  to  evaluate
he  efﬁcacy  of  the  combination  treatment  with  nilutamide
lus  buserelin  and  to  describe  the  occurrence  of  adverse
vents  (AEs)  associated  with  that  treatment.
aterials and methods
 descriptive,  prospective  study  evaluated  patients  with  CaP
eceiving  nilutamide  and  buserelin,  at  baseline  and  at  3,  6,
nd  9  months.
Six  centers  participated  in  this  study:  5  in  Mexico  City
nd  one  in  Morelia.  All  the  centers  are  community-based
ospitals.
The  attending  urologists  were  the  investigators,  and  were
irectly  responsible  for  the  treatment  of  the  CaP  patients  at
ach  center.
The  Mexican  Urological  Association  Ethics  Committee
ssessed  and  approved  the  study.
nclusion  criteria
.  Males  with  biopsy-proven  CaP
.  Age  > 18  years
.  Signed  Informed  consent
.  Measurable  or  evaluable  disease
.  No  previous  surgery  to  remove  the  testesThe  treatment  scheme  consisted  of  300  mg  of  nilutamide
150  mg  P.O.  every  12  h)  for  4  weeks,  and  then  150  mg  P.O.
aily  for  8  months  plus  9.45  mg  of  buserelin  bi-monthly  in
he  form  of  a  subcutaneous  implant.
D
A
i
Table  1  Demographic  data  of  the  patients  included  in  this  study.
Saf
n =
Age,  mean  (SD)  
Age >70  years,  n  (%)  
Family history  of  cancer,  n  (%)  
Family history  of  CaP,  n  (%)  
Comorbidities
High blood  pressure,  n  (%)  
Diabetes, n  (%)  
Dyslipidemia,  n  (%)  
Other diseases,  n  (%)
Baseline PSA,  mean  (SD)  13.
Gleason score  <7,  n  (%)  
Gleason score  =7,  n  (%)  
Gleason score  >7,  n  (%)  
BMI, mean  (SD)  25.
BMI >27,  n  (%)  
BMI, body mass index; CaP, prostate cancer; PSA, prostate-speciﬁc antR.F.  Velázquez-Macías  et  al.
fﬁcacy  criteria
rimary  endpoints
.  At  least  50%  reduction  of  serum  PSA  from  the  baseline
value
.  Total  PSA  levels  <10  ng/ml
Secondary  endpoints
.  No  increase  of  PSA  levels  at  9-month  follow-up
.  Undetectable  PSA  values  at  9-month  follow-up
.  No  clinical  evidence  of  disease  progression  during  the
study  period
ata  collection
 case  report  form  (CRF)  for  data  collection  was  designed.
nformation  was  manually  collected  by  the  attending  urol-
gist.  At  the  end  of  the  study,  all  CRFs  were  gathered  and
ubmitted  for  data  compilation  and  analysis  by  INNOVAL,  a
ata  management  company.  The  variables  registered  and
nalyzed  were:  age  (in  years),  body  height  (in  centime-
ers),  body  weight  (in  kilograms),  body  mass  index,  general
emographic  variables,  CaP  family  history,  co-morbidities,
leason  score,  prostate-speciﬁc  antigen  value  (PSA,  in
g/ml),  Karnofsky  score,  and  adverse  events.  During  each
isit,  the  primary  endpoints  were  determined,  as  well  as  the
arnofsky  score  and  the  presence  of  adverse  events.  Previ-
usly  reported  adverse  events  associated  with  nilutamide
nd  buserelin  were  speciﬁcally  investigated,  but  sponta-
eous  reports  were  also  registered  in  the  CRF.ata  management,  review,  and  validation
ll  medical  records  were  handled  and  kept  at  each  partic-
pating  center.  A  study  monitor  performed  2--4  site  visits
ety  analysis  Efﬁcacy  analysis
 104  n  =  67
72  (8.7)  71.9  (9.5)
64  (61.5)  39  (58.2)
14  (20.9)  9  (13.4)
7  (6.7)  4  (6.0)
28  (26.9)  16  (23.9)
9  (8.6)  5  (7.5)
3  (2.8)  1  (1.5)
19  (18.3)  11  (16.4)
00  (279.13)  53.72  (131.62)
52  (50)  34  (50.7)
35  (33.6)  22  (32.8)
13  (12.5)  11  (16.4)
96  (3.6)  26.2  (3.3)
37  (35.9)  21  (31.3)
igen; SD, standard deviation.
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Table  2  Efﬁcacy  analysis:  study  outcomes  at  9  months.
Characteristic  n  =  67
At  least  50%  PSA  reduction 63  (94.0)
PSA <10  ng/ml  65  (97.0)
50% PSA  reduction  or  <10  ng/ml  65  (97.0)
No PSA  increase  63  (94.0)
PSA increase  7  (6.8)
Negative  PSA  4  (6.0)
100
80
60
40
20
0
Visit 1(basal) Visit 2(3 mo)
p = 0,002∗
p = 0,002∗
Error bars: +/- 2 se of means 
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Visit 3(6 mo) Visit 4(9 mo)
Figure  1  Efﬁcacy  analysis:  prostate-speciﬁc  antigen  (PSA)
changes  over  the  study  period.  *p  Values  for  the  differences
in mean  PSA  with  respect  to  baseline  measure:  paired-sample
t test.
Table  3  Safety  analysis:  adverse  events  reported  during
the study  period.
Adverse  effects  (n  =  104),  n  (%)
Related  to  drug  intervention
Serious  adverse  effects
Deaths  0
Life-threatening  events 0
Hospitalizations  0
Other  non-serious  adverse  events
Hot  ﬂushes  6  (5.58)
Muscle  or  skeletal  pain  1  (0.96)
Hyperglycemiaa 1  (0.96)
Erectile  dysfunction  1  (0.96)
Abnormal  liver  function  tests  0
Appetite  changes  0
Injection  site  reaction  0
Skin changes  0
Unrelated  to  drug  intervention
Serious  adverse  effects
Deaths  2  (1.9)
Life-threatening  events  0
Hospitalization  2  (1.9)
Other non-serious  adverse  events
Other  non-serious  adverse  events
Gastrointestinal  changes  0
Respiratory  changes  0
Hematologic  abnormalities  0
Glucose  metabolism  abnormalities  0
Headache  0
Weakness  0
a Hyperglycemia to 114 mg/dl (6.33 mmol/l).
i
eAll values  n  (%)
PSA, prostate-speciﬁc antigen.
for  data  review  and  validation  during  the  study  period.  The
study  monitor  evaluated  data  accuracy,  and  gathered  the
CRF  sheets  containing  all  the  information  at  the  end  of
the  study.
The  ﬁnal  PSA  values  were  compared  with  pre-treatment
PSA  values  with  a  paired  two-sample  t-test  after  each  visit.
When  the  outlier  values  affected  the  t-test,  a  Friedman  test
was  used  to  adjust  the  extreme  values.  The  Karnofsky  scale
was  analyzed  using  the  Friedman  test3.
Results
A  total  of  104  patients  with  biopsy-proven  CaP  that  received
nilutamide  plus  buserelin  were  identiﬁed  and  their  data
were  used  for  the  safety  analysis.  However,  37  patients
were  excluded  from  the  ﬁnal  analysis:  15  were  lost  to
follow-up  (total  follow-up:  21  months),  20  had  incomplete
PSA  information  or  a  non-measurable  effect  (undetectable
serum  PSA  at  the  baseline),  and  two  patients  died  due
to  causes  unrelated  to  the  drug  intervention.  There-
fore,  for  efﬁcacy  analysis  purposes,  data  from  67  patients
were  analyzed  (Table  1):  65  (97.0%)  reached  the  combi-
nation  primary  outcome  of  50%  reduction  in  PSA  levels
from  the  baseline  (n  =  63,  94.0%)  or  PSA  levels  <10  ng/ml
(n  =  2,  97.0%).  Sixty-three  (94.0%)  patients  achieved  the
secondary  outcome  of  no  increase  in  PSA  levels  at  the
follow-up  at  9  months  (visit  4).  Thirty-ﬁve  (52.2%)  of
the  patients  achieved  undetectable  PSA  values  at  the  9th-
month  follow-up.  Disease  progression  (i.e.,  increased  PSA
levels  from  the  baseline  values)  occurred  in  4  (6.0%)  patients
(Table  2).
None  of  the  registered  variables  appeared  to  inﬂuence
treatment  response  in  the  univariate  analyses.  A  highly
signiﬁcant  difference  was  observed  in  the  mean  baseline
PSA  values  and  those  reached  at  visit  4  (at  follow-up
at  9  months):  53.72  ±  131.62  ng/ml  vs.  1.58  ±  8.47  ng/ml,
respectively;  p  =  0.002  (Fig.  1).  The  mean  Karnofsky  perfor-
mance  score  improved  signiﬁcantly  from  the  baseline  to  visit
4  (92.69  vs.  97.61,  respectively;  p  =  0.02).
The  combination  therapy  was  well  tolerated,  with  only
7  patients  reporting  adverse  events.  These  events  were
mild,  and  did  not  require  treatment  suspension  or  any
additional  speciﬁc  treatment.  Six  patients  (5.8%)  reported
hot  ﬂushes.  Muscle/skeletal  pain,  mild  hyperglycemia
(<7  mmol/l),  and  erectile  dysfunction  were  each  reported
by  one  patient  (0.9%).
Of  the  104  study  patients,  two  died  after  visit  1:
one  patient  with  metabolic  syndrome  had  myocardial
e
u
c
enfarction,  and  one  patient  with  high  blood  pressure,  appar-
ntly  under  control,  had  intracerebral  hemorrhage.  Both
vents  required  hospitalization  and  were  ﬁnally  considered
nrelated  to  the  drug  intervention  by  the  investigator  in
harge  of  each  case.  We  observed  no  other  major  adverse
vents,  including  cardiovascular  effects  (Table  3).
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iscussion
aP  control  was  successfully  achieved  in  most  of  the  patients
valuated  in  the  efﬁcacy  analysis  (67  out  of  104  patients)
uring  the  9-month  study  period,  as  evidenced  by  the  very
ow  levels  of  PSA  found  in  our  patients  at  all  study  visits.  Sig-
iﬁcant  and  sustained  reduction  in  PSA  values  was  quickly
chieved  from  the  ﬁrst  3  months  of  treatment  with  nilu-
amide  plus  buserelin.
These  results  are  consistent  with  other  published  studies.
n  the  study  by  Choo  et  al.,13 in  which  androgen  suppression
onsisted  of  oral  nilutamide  100  mg  three  times  daily  for
 weeks  and  buserelin  acetate  6.3  mg  subcutaneous  depot
very  2  months  for  2  years  for  patients  with  pathologic
3  disease  and/or  positive  surgical  margins  after  radical
rostatectomy,  they  found  that  49  out  of  78  patients  had
ndetectable  PSA  (<0.2  ng/ml)  and  a  5-year  survival  rate  of
6%.
In  another  study  by  Castan˜eda  et  al.,14 27  patients  with
denocarcinoma  of  the  prostate  in  locally  advanced  and
etastatic  stages  were  initially  treated  with  an  antian-
rogen  plus  a  LHRH  analog,  leaving  this  last  drug  as
onotherapy  once  the  nadir  of  the  PSA  was  reached.  They
ound  that  in  all  but  2  patients,  the  PSA  level  reached  its
adir  point  after  the  third  application  of  the  LHRH  analog.
n  the  study  by  Ricardez-Espinoza  et  al.,15 30  patients  were
reated  with  intermittent  ADT  with  goserelin  and  bicalu-
amide  and  90%  of  them  showed  PSA  levels  <0.2  ng/ml  after
 months  of  treatment.
Kassouf  et  al.,16 showed  that  up  to  64%  of  patients
ith  advanced  CaP  and  failed  androgen  ablation  achieved
 signiﬁcantly  sustained  PSA  response  and  favorable  toxicity
roﬁle  with  nilutamide  administration.  They  also  found  that
atients  with  a  previous  antiandrogen  withdrawal  response
ad  a  signiﬁcantly  greater  chance  of  responding  to  nilu-
amide.  This  drug  has  also  been  associated  with  a  50%  or
reater  decrease  in  PSA  in  about  one  third  of  patients,
ith  a  typical  median  response  duration  of  4--7  months17
n  patients  with  failed  ﬂutamide  use  or  upon  antiandrogen
ithdrawal.18
In  addition,  data  from  a  retrospective  analysis  show
hat  a  50%  or  greater  decrease  in  PSA  at  12  weeks,
egardless  of  the  therapy  employed,  more  than  doubled
atient  survival.19 These  data  have  also  been  supported  by
rospective  studies20 and  are  currently  included  in  Mexican
uidelines.21
A  study  by  Rodriguez  et  al.,22 evaluated  QoL  in  patients
ith  advanced  CaP  treated  with  nilutamide  once  a  day  and
ubcutaneous  buserelin  every  two  months.  They  proposed
his  combination  therapy  as  an  alternative  to  surgical  castra-
ion,  advocating  its  effectiveness  in  the  control  of  advanced
ases  and  the  improvement  in  patient  quality  of  life,  given
hat  they  found  no  increase  in  the  frequency  of  speciﬁc
dverse  events  with  either  drug.
Despite  the  treatment  efﬁcacy  we  found  in  our  patients,
ur  study  had  certain  limitations,  the  most  important  of
hich  was  the  short  follow-up  period,  which  prevented  us
rom  performing  a  survival  analysis.  Nevertheless,  based
n  the  abovementioned  studies,  we  theorize  that  survival
urves  would  not  be  dissimilar  to  those  reported  in  the  inter-
ational  literature.
o
R
dR.F.  Velázquez-Macías  et  al.
Another  drawback  was  the  high  number  of  patients
hat  had  to  be  excluded  from  the  efﬁcacy  analysis:  14.4%
15  patients)  were  lost  to  follow-up,  20  more  patients  had  to
e  excluded  due  to  lack  of  PSA  information,  and  there  were
wo  deaths,  producing  a  total  patient  loss  of  35.6%  in  our
tudy.  This  fact  was  most  likely  a  source  of  bias  in  our  ﬁnal
tudy  results,  because  the  reasons  for  patient  data  unavail-
bility  are  clearly  associated  with  the  outcome  of  interest
PSA  serum  levels).
On  the  other  hand,  our  ﬁndings  support  a good  response
o  MAB  achieved  through  the  use  of  nilutamide  and  buserelin
y  using  PSA  as  a  marker  for  disease  progression.  We  chose
SA  as  an  endpoint  because  of  its  simplicity,  repeatability,
eproducibility,  and  clear  association  with  the  disease  time
ourse.  However,  it  is  to  be  noted  that  sometimes  changes
n  PSA  values  may  or  may  not  solely  reﬂect  treatment.23
herefore,  we  view  our  present  work  as  a proof-of-concept
tudy  to  facilitate  a  new  project  that  includes  long-term
ollow-up.
Finally,  we  observed  two  deaths  in  this  study:  one  case
f  myocardial  infarction  (MI)  and  one  case  of  stroke.  In
his  regard,  we  are  conﬁdent  that  these  deaths  were  not
elated  to  the  treatment.  First  of  all,  the  attending  physi-
ian  of  each  case  carried  out  a  thorough  patient  evaluation,
hich  revealed  the  presence  of  vascular  risk  factors  that
ade  both  patients  high-risk  proﬁle  carriers  for  cardio  and
erebrovascular  disease.  Moreover,  despite  the  fact  that  an
ncreased  risk  of  cardiovascular  disease  has  been  previously
ocumented,  a  recent  meta-analysis  found  that  ADT  use,  at
east  for  buserelin,24 was  not  associated  with  an  increased
isk  of  cardiovascular  death,  and  was  associated  with  a
ower  risk  of  prostate  cancer-speciﬁc  mortality  and  all-cause
ortality.25 This  has  led  to  the  proposal  that  until  the  direc-
ion  of  the  association  between  ADT  and  cardiovascular  risk
s  conﬁrmed  in  a suitable  experimental  study,  the  effect  of
DT  on  cardiovascular  risk  should  be  cautiously  interpreted
ithin  the  context  of  the  available  information.26
onclusion
n  this  study,  treatment  with  nilutamide  plus  buserelin  was
afe  and  effective  in  controlling  disease  activity  in  advanced
rostate  cancer  patients.  The  high  number  of  patients  that
eached  the  primary  endpoint  in  our  efﬁcacy  analysis  sup-
orts  this  afﬁrmation.  Based  on  our  ﬁndings,  we  aim  to
erform  a  larger  randomized  placebo-controlled  clinical
rial  to  evaluate  the  role  of  MAB  on  patient  survival,  using
he  combination  therapy  of  nilutamide  plus  buserelin.
thical responsibilities
rotection  of  people  and  animals.  The  authors  state  that
or  this  investigation  have  not  been  performed  experiments
n  humans  or  animals.
onﬁdentiality  of  data.  The  authors  declare  that  they  have
ollowed  the  protocols  of  the  workplace  on  the  publication
f  patient  data.
ight  to  privacy  and  informed  consent.  The  authors
eclare  that  this  article  does  not  appear  patient  data.
n  ma
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2Evaluation  of  efﬁcacy  of  buserelin  plus  nilutamide  in  Mexica
Financing
Sanoﬁ-Aventis  contract  an  independent  company  for  statis-
tical  processing  of  this  study,  as  well  as  providing  scientiﬁc
and  technical  advice.
Conﬂict of interests
The  authors  declare  no  conﬂict  of  interest.
Acknowledgments
The  authors  wish  to  thank  Dr.  Fernando  Mendoza-Pen˜a,  Head
of  the  Urology  service  of  the  Hospital  Regional  Licenciado
Adolfo  López  Mateos  for  his  support  in  allowing  the  present
study  to  be  conducted  in  said  Service.
References
1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and
prostate-cancer mortality in a randomized European study. N
Engl J Med. 2009;360:1320--8.
2. Merayo-Chalico CE, Sánchez-Turati GJ, Santana-Ríos Z, et al.
Prevalencia del cáncer de próstata incidental en el Hospital
General Dr. Manuel Gea González; 20 an˜os de revisión. Rev Mex
Urol. 2009;69:147--52.
3. Aapro MS. Management of advanced prostate cancer in senior
adults: the new landscape. Oncologist. 2012;17 Suppl. 1:
16--22.
4. Ramírez-Gallardo GA, Contreras-González N, David R-B. Expe-
riencia con bloqueo androgénico para pacientes con cáncer de
próstata avanzado, en el Hospital General Tacuba, ISSSTE. Rev
Mex Urol. 2003;63:137--9.
5. Droz JP, Balducci L, Bolla M, et al. Background for the proposal
of SIOG guidelines for the management of prostate cancer in
senior adults. Crit Rev Oncol Hematol. 2010;73:68--91.
6. Brawer MK. Hormonal therapy for prostate cancer. Rev Urol.
2006;8 Suppl. 2:S35--47.
7. Arroyo-Kuribren˜a JC, Soto-Vega E, Mun˜oz-Pérez M, et al.
Bloqueo androgénico en cáncer de próstata, revisión de la lit-
eratura. Rev Mex Urol. 2012;72:182--96.
8. Seidenfeld J, Samson DJ, Aronson N, et al. Relative effective-
ness and cost-effectiveness of methods of androgen suppression
in the treatment of advanced prostate cancer. Evid Rep Technol
Assess (Summ). 1999;i--x:1--246. I241--236, passim.
9. Chodak GW. Maximum androgen blockade: a clinical update.
Rev Urol. 2005;7 Suppl. 5:S13--7.
10. Maximum androgen blockade in advanced prostate cancer: an
overview of the randomised trials. Prostate Cancer Trialists’
Collaborative Group. Lancet. 2000;355:1491--8.
11. Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible
utility as a second-line hormonal agent. Urology. 2001;58:
1016--20.le  patients  351
2. Kuhn JM, Billebaud T, Navratil H, et al. Prevention of the
transient adverse effects of a gonadotropin-releasing hor-
mone analogue (buserelin) in metastatic prostatic carcinoma by
administration of an antiandrogen (nilutamide). N Engl J Med.
1989;321:413--8.
3. Choo R, Danjoux C, Gardner S, et al. Prospective study
evaluating postoperative radiotherapy plus 2-year androgen
suppression for post-radical prostatectomy patients with patho-
logic T3 disease and/or positive surgical margins. Int J Radiat
Oncol Biol Phys. 2009;75:407--12.
4. Castan˜eda-Sánchez JdJ, Manzanilla-García H, Torres-Saunders
C, et al. Bloqueo androgénico total en el tratamiento del cáncer
avanzado de próstata. Experiencia a largo plazo. Rev Mex Urol.
2001:61.
5. Ricardez-Espinosa AA, Rodríguez-Esqueda M, Ricardez-Arenas
AA, et al. Hormonoterapia intermitente para el manejo
de cáncer de próstata. Reporte preliminar. Rev Mex Urol.
2001;61:184--92.
6. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line
hormone therapy for prostate cancer after androgen ablation
fails. J Urol. 2003;169:1742--4.
7. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroi-
dal antiandrogen therapy for advanced prostate cancer that
relapsed after initial maximum androgen blockade. J Urol.
2008;180:921--7.
8. Molina A, Belldegrun A. Novel therapeutic strategies for castra-
tion resistant prostate cancer: inhibition of persistent androgen
production and androgen receptor mediated signaling. J Urol.
2011;185:787--94.
9. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed
prostate cancer: deﬁning the target. J Natl Cancer Inst.
1996;88:1623--34.
0. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal
alone or in combination with ketoconazole in androgen-
independent prostate cancer patients: a phase III trial (CALGB
9583). J Clin Oncol. 2004;22:1025--33.
1. Jiménez-Ríos MÁ, Solares-Sánchez M, Martínez-Cervera P, et al.
Oncoguía: Cáncer de Próstata. Cancerología. 2011:13--8.
2. Rodríguez-Rivera JA, Gabilondo-Navarro F, Vega-Serrano R,
et al. Study to evaluate quality of life in patients with advanced
prostate cancer, under treatment using the combination of
buserelin plus nilutamide. Rev Mex Urol. 2005;65:398--406.
3. Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal
therapy for advanced prostate cancer. J Urol. 2006;175:27--34.
4. Sanoﬁ-aventis Canada Inc. SUPREFACT® DEPOT 2 months and
SUPREFACT® DEPOT 3 months product monograph. Laval, Que-
bec; 2006.
5. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen
deprivation therapy with cardiovascular death in patients with
prostate cancer: a meta-analysis of randomized trials. JAMA.
2011;306:2359--66.
6. Schooling CM, Sembajwe G, Agalliu I.Androgen-deprivation
therapy in treatment of prostate cancer and risk of
myocardial infarction and stroke: a nationwide Danish
population-based cohort study. Eur Urol. 2013;64:e59--60,
http://dx.doi.org/10.1016/j.eururo.2013.02.002 [in press].
